"I am glad that taking part in a trial might help others on their own cancer journey.”
A trial looking at PM01183 for pancreatic cancer
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug PM01183 to treat pancreatic cancer that has spread to other parts of the body.
Pancreatic cancer that has spread to other parts of the body is sometimes called advanced pancreatic cancer. Doctors usually treat this with chemotherapy including the drug gemcitabine. Sadly this doesn’t always work very well so doctors want to find new drugs to help people with advanced pancreatic cancer.
PM01183 is a new drug that affects how cancer cells divide and grow. Researchers want to find out if it can help people with advanced pancreatic cancer.
The aim of this trial is to find out
- If PM01183 can help people with advanced pancreatic cancer that has come back or did not go away with chemotherapy
- About the side effects
Who can enter
You may be able to enter this trial if you
- Have pancreatic cancer that has spread to other parts of your body (advanced pancreatic cancer)
- Have pancreatic cancer that didn’t get better with treatment or came back after treatment with gemcitabine
- Are well enough to carry out all your normal activities, apart from heavy physical work (performance status of 0 or 1)
- Have satisfactory blood tests results
- Are well enough to have treatment
- Are willing to use reliable contraception during treatment and for 6 months afterwards if there is any chance that you or your partner could become pregnant
- Are aged between 18 and 75 years old
You cannot enter this trial if you
- Have a type of pancreatic cancer known as neuroendocrine or mucinous
- Have already had more than one course of chemotherapy for your pancreatic cancer
- Have cancer that has spread to your brain
- Have had any other cancer, apart from carcinoma in situ of the cervix, non melanoma skin cancer or carcinoma in situ of the bladder that was successfully treated at least 3 years ago
- Are HIV, hepatitis B or C positive
- Have had chemotherapy in the last 2 weeks
- Have had radiotherapy in the last month
- Have had PM01183 before
- Have a swollen tummy due to a collection of fluid (
- Have a blood clot in your leg (deep vein thrombosis or DVT) that is not getting better with treatment
- Have had a heart attack in the last year or any other serious heart condition that is not well controlled with medication
- Have an infection that cannot be controlled by medication, or any other condition that could make it unsafe for you to take part in this trial
- Have had an experimental drug as part of another trial if it is still affecting you - your doctor can discuss this with you
This trial will recruit up to 43 people. Every one taking part has PM01183.
You have PM01183 through a drip into a vein once every 3 weeks. Each 3 week period is called a cycle of treatment. You can have PM01183 for as long as it is helping you and you want to continue with the treatment.
If you agree to take part in this study, the researchers will ask for a sample of tissue taken when your cancer was diagnosed. If you don’t want to give tissue samples for this study, you don’t have to. You can still take part in the trial.
You see the doctors and have some tests before you start treatment. The tests include
- Blood tests
- Physical examination
- Heart trace (
- Heart ultrasound (
echocardiogram) or MUGA scan
- CT scan or MRI scan
You have physical examinations and blood tests frequently while you are having treatment.
You have a CT scan or MRI scan every 6 weeks while you have treatment and until your cancer starts to grow again.
When you stop treatment the researchers will see you 30 days later for blood tests.
If you stop treatment because your cancer has started to grow, the researchers will see you every 3 months for a year.
If you stop treatment and your cancer has not got worse then the researchers see you every 6 weeks until your cancer starts to grow again.
How to join a clinical trial
Dr David Cunningham